Clinuvel Pharmaceuticals (FRA:UR9A) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:UR9A Clinuvel Pharmaceuticals Ltd FRA:UR9A
79 GF Score
Price €5.90
GF Value €10.40
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Clinuvel Pharmaceuticals Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:UR9A
79GF Score
Clinuvel Pharmaceuticals Ltd FRA:UR9A
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Clinuvel Pharmaceuticals (FRA:UR9A) Overvalued in 2026?

Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued. The current stock price of €5.90 is trading 43.3% below its estimated GF Value™ of €10.40. GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for FRA:UR9A:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €10.40 vs. price of €5.90 (43.3% below fair value)
  • GF Score™: 79/100 with 2 warning signs

No single metric tells the full story. See the FRA:UR9A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clinuvel Pharmaceuticals Business Description

Address 535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
79GF Score

Get the complete analysis for FRA:UR9A

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.90
Price
€10.40
GF Value